OncoSec Medical Inc (ONCSQ)

[NY1972]

T-VEC with ipilimumab(NCT02263508)

Early data has demonstrated an ORR of 56 % (33 % complete response rate) with a median PFS of 10.6 months. OS at 12 and 18 months was 72.2 % and 67 %, respectively; however, these results are likely influenced by the inclusion of stage III patients in the study. T-VEC is also being studied in combination with anti-PD-1 therapy. A randomized, open label trial of T-VEC plus pembrolizumab versus pembrolizumab alone is actively enrolling patients with unresectable stage IIIB–IV

4-1BB agonist PF-05082566 plus pembrolizumab (NCT02179918)
OX40 ligand fusion protein MEDI6383 in combination with durvalumab (NCT02221960)
CD27 agonist varililumab in combination with nivolumab (NCT02335918)

pembrolizumab plus epacadostat
Preliminary data presented at the 2015 SITC general meeting showed objective responses in four out of seven patients with melanoma evaluable at the time of the report.